MA49641A - Traitement de lésions non inflammatoires - Google Patents

Traitement de lésions non inflammatoires

Info

Publication number
MA49641A
MA49641A MA049641A MA49641A MA49641A MA 49641 A MA49641 A MA 49641A MA 049641 A MA049641 A MA 049641A MA 49641 A MA49641 A MA 49641A MA 49641 A MA49641 A MA 49641A
Authority
MA
Morocco
Prior art keywords
treatment
inflammatory lesions
lesions
inflammatory
Prior art date
Application number
MA049641A
Other languages
English (en)
Inventor
David Berk
Alexandre Kaoukhov
Carsten Schmitz
Vilma Sniukiene
Original Assignee
Almirall Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Llc filed Critical Almirall Llc
Publication of MA49641A publication Critical patent/MA49641A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA049641A 2017-07-21 2018-07-20 Traitement de lésions non inflammatoires MA49641A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762535572P 2017-07-21 2017-07-21

Publications (1)

Publication Number Publication Date
MA49641A true MA49641A (fr) 2021-06-02

Family

ID=63713912

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049641A MA49641A (fr) 2017-07-21 2018-07-20 Traitement de lésions non inflammatoires

Country Status (13)

Country Link
US (1) US20200222432A1 (fr)
EP (1) EP3654988B1 (fr)
JP (1) JP2020527607A (fr)
KR (1) KR102662461B1 (fr)
CN (1) CN111343991A (fr)
AU (1) AU2018303807B2 (fr)
BR (1) BR112020000968A2 (fr)
CA (1) CA3070663A1 (fr)
ES (1) ES2962380T3 (fr)
IL (1) IL272124A (fr)
MA (1) MA49641A (fr)
MX (1) MX2020000816A (fr)
WO (1) WO2019016609A1 (fr)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (fr) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
JP2004536046A (ja) * 2001-04-05 2004-12-02 コッラジェネックス ファーマシューチカルス インコーポレイテッド ざ瘡の治療方法
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
CA2892739A1 (fr) * 2006-12-21 2008-07-03 Paratek Pharmaceuticals, Inc. Utilisation de composes a base de tetracycline substituee dans le traitement d'affections cutanees inflammatoires
EP2452935A3 (fr) 2006-12-21 2012-08-29 Paratek Pharmaceuticals, Inc. Dérivés de tétracycline pour le traitement d'infections bactériennes, virales et parasites
US9132139B2 (en) * 2008-05-21 2015-09-15 Galderma Research & Development Maintenance therapy regime/regimen for the treatment of acne
EP2299810B1 (fr) * 2008-06-05 2020-01-01 Bausch Health Ireland Limited Formulations pharmaceutiques topiques contenant une faible concentration de peroxyde de benzoyle en suspension dans de l'eau et un solvant organique miscible avec l'eau
CA2769640A1 (fr) * 2009-07-30 2011-02-03 Allergan, Inc. Combinaison du dapsone avec l'adapalene
US20140121188A1 (en) * 2009-10-02 2014-05-01 Foamix Ltd. Compositions for the improved treatment of acne and related disorders
EP3574908B8 (fr) 2011-05-12 2024-09-11 Almirall LLC Composition pharmaceutique pour adminstration par voie orale comprenant des sels cristallins d'amide de l'acide (4s,4as,5ar,12as)-4-diméthylamino- 3,10,12,12a-tétrahydroxy-7-[(méthoxy(méthyl)amino)-méthyl]- 1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphtacène-2-carboxylique
CA2867419C (fr) * 2012-03-15 2023-10-24 Foamix Ltd. Utilisation de compositions de tetracycline pour le traitement des blessures et la restauration de la peau
GB201615693D0 (en) * 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations

Also Published As

Publication number Publication date
ES2962380T3 (es) 2024-03-18
EP3654988B1 (fr) 2023-09-06
BR112020000968A2 (pt) 2020-07-14
US20200222432A1 (en) 2020-07-16
CA3070663A1 (fr) 2019-01-24
AU2018303807A1 (en) 2020-02-13
JP2020527607A (ja) 2020-09-10
AU2018303807B2 (en) 2023-08-24
EP3654988A1 (fr) 2020-05-27
KR102662461B1 (ko) 2024-04-30
KR20200031126A (ko) 2020-03-23
MX2020000816A (es) 2020-08-17
CN111343991A (zh) 2020-06-26
IL272124A (en) 2020-03-31
WO2019016609A1 (fr) 2019-01-24

Similar Documents

Publication Publication Date Title
MA50056A (fr) Procédés de traitement de tumeur
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA43374A (fr) Méthodes de traitement de tumeurs malignes
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
IL253945B (en) kdm1a inhibitors to treat the disease
MA41449A (fr) Polythérapies pour le traitement de cancers
MA43190A (fr) Traitement de la dyslipidémie mixte
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
MA47719A (fr) Esketamine pour le traitement de la dépression
IL275496A (en) Glycolate oxidase inhibitors to treat the disease
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA47408A (fr) Traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
IL264048A (en) pde9 inhibitors for the treatment of peripheral diseases
MA47558A (fr) Traitement de la fibrose
MA48637A (fr) Polythérapies pour le traitement du cancer
MA46361A (fr) Traitement du cancer de la prostate
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA47820A (fr) Traitement de la glycogénose de type iii
MA49059A (fr) Traitement des cancers positifs à her2
MA42999A (fr) Polythérapie pour le traitement de malignités
MA52627A (fr) Traitement du cancer
MA42930A (fr) Traitement de maladies neurodégénératives